376 related articles for article (PubMed ID: 25029236)
1. Combination of antiangiogenic therapy using the mTOR-inhibitor everolimus and low-dose chemotherapy for locally advanced and/or metastatic pancreatic cancer: a dose-finding study.
Joka M; Boeck S; Zech CJ; Seufferlein T; Wichert Gv; Licht T; Krause A; Jauch KW; Heinemann V; Bruns CJ
Anticancer Drugs; 2014 Oct; 25(9):1095-101. PubMed ID: 25029236
[TBL] [Abstract][Full Text] [Related]
2. A phase I dose-escalation study of lenalidomide in combination with gemcitabine in patients with advanced pancreatic cancer.
Ullenhag GJ; Rossmann E; Liljefors M
PLoS One; 2015; 10(4):e0121197. PubMed ID: 25837499
[TBL] [Abstract][Full Text] [Related]
3. A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer.
Ko AH; Truong TG; Kantoff E; Jones KA; Dito E; Ong A; Tempero MA
Cancer Chemother Pharmacol; 2012 Dec; 70(6):875-81. PubMed ID: 23053263
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine Combined with the mTOR Inhibitor Temsirolimus in Patients with Locally Advanced or Metastatic Pancreatic Cancer. A Hellenic Cooperative Oncology Group Phase I/II Study.
Karavasilis V; Samantas E; Koliou GA; Kalogera-Fountzila A; Pentheroudakis G; Varthalitis I; Linardou H; Rallis G; Skondra M; Papadopoulos G; Papatsibas G; Sgouros J; Goudopoulou A; Kalogeras KT; Dervenis C; Pectasides D; Fountzilas G
Target Oncol; 2018 Dec; 13(6):715-724. PubMed ID: 30488350
[TBL] [Abstract][Full Text] [Related]
5. A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma.
Harzstark AL; Small EJ; Weinberg VK; Sun J; Ryan CJ; Lin AM; Fong L; Brocks DR; Rosenberg JE
Cancer; 2011 Sep; 117(18):4194-200. PubMed ID: 21387258
[TBL] [Abstract][Full Text] [Related]
6. A phase I radiation dose-escalation study to determine the maximal dose of radiotherapy in combination with weekly gemcitabine in patients with locally advanced pancreatic adenocarcinoma.
Budiharto T; Haustermans K; Van Cutsem E; Van Steenbergen W; Topal B; Aerts R; Ectors N; Bielen D; Vanbeckevoort D; Goethals L; Verslype C
Radiat Oncol; 2008 Sep; 3():30. PubMed ID: 18808686
[TBL] [Abstract][Full Text] [Related]
7. Phase I dose-finding study of vandetanib in combination with gemcitabine in locally advanced unresectable or metastatic pancreatic adenocarcinoma.
Saletti P; Sessa C; De Dosso S; Cerny T; Renggli V; Koeberle D
Oncology; 2011; 81(1):50-4. PubMed ID: 21921646
[TBL] [Abstract][Full Text] [Related]
8. A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma.
Duffy A; Kortmansky J; Schwartz GK; Capanu M; Puleio S; Minsky B; Saltz L; Kelsen DP; O'Reilly EM
Ann Oncol; 2008 Jan; 19(1):86-91. PubMed ID: 17878176
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of everolimus, gemcitabine and cisplatin in patients with solid tumors.
Costello BA; Borad MJ; Qi Y; Kim GP; Northfelt DW; Erlichman C; Alberts SR
Invest New Drugs; 2014 Aug; 32(4):710-6. PubMed ID: 24740268
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer.
Kordes S; Klümpen HJ; Weterman MJ; Schellens JH; Richel DJ; Wilmink JW
Cancer Chemother Pharmacol; 2015 Jun; 75(6):1135-41. PubMed ID: 25822310
[TBL] [Abstract][Full Text] [Related]
11. A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer.
Cohen SJ; Zalupski MM; Modiano MR; Conkling P; Patt YZ; Davis P; Dorr RT; Boytim ML; Hersh EM
Cancer Chemother Pharmacol; 2010 Jul; 66(2):287-94. PubMed ID: 19855966
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors.
Chan JA; Mayer RJ; Jackson N; Malinowski P; Regan E; Kulke MH
Cancer Chemother Pharmacol; 2013 May; 71(5):1241-6. PubMed ID: 23475104
[TBL] [Abstract][Full Text] [Related]
13. A phase 1/1B trial of ADI-PEG 20 plus nab-paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinoma.
Lowery MA; Yu KH; Kelsen DP; Harding JJ; Bomalaski JS; Glassman DC; Covington CM; Brenner R; Hollywood E; Barba A; Johnston A; Liu KC; Feng X; Capanu M; Abou-Alfa GK; O'Reilly EM
Cancer; 2017 Dec; 123(23):4556-4565. PubMed ID: 28832976
[TBL] [Abstract][Full Text] [Related]
14. Multi-institutional phase I study of low-dose ultra-fractionated radiotherapy as a chemosensitizer for gemcitabine and erlotinib in patients with locally advanced or limited metastatic pancreatic cancer.
Konski A; Meyer JE; Joiner M; Hall MJ; Philip P; Shields A; McSpadden E; Choi M; Adaire B; Duncan G; Meropol NJ; Cescon TP; Cohen SJ
Radiother Oncol; 2014 Oct; 113(1):35-40. PubMed ID: 25441058
[TBL] [Abstract][Full Text] [Related]
15. Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies.
Deenen MJ; Klümpen HJ; Richel DJ; Sparidans RW; Weterman MJ; Beijnen JH; Schellens JH; Wilmink JW
Invest New Drugs; 2012 Aug; 30(4):1557-65. PubMed ID: 21809026
[TBL] [Abstract][Full Text] [Related]
16. A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma.
Bitting RL; Healy P; Creel PA; Turnbull J; Morris K; Wood SY; Hurwitz HI; Starr MD; Nixon AB; Armstrong AJ; George DJ
Clin Genitourin Cancer; 2014 Aug; 12(4):241-50. PubMed ID: 24685058
[TBL] [Abstract][Full Text] [Related]
17. Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma.
O'Reilly EM; Lee JW; Lowery MA; Capanu M; Stadler ZK; Moore MJ; Dhani N; Kindler HL; Estrella H; Maynard H; Golan T; Segal A; Salo-Mullen EE; Yu KH; Epstein AS; Segal M; Brenner R; Do RK; Chen AP; Tang LH; Kelsen DP
Cancer; 2018 Apr; 124(7):1374-1382. PubMed ID: 29338080
[TBL] [Abstract][Full Text] [Related]
18. A phase I trial of cabozantinib and gemcitabine in advanced pancreatic cancer.
Zhen DB; Griffith KA; Ruch JM; Camphausen K; Savage JE; Kim EJ; Sahai V; Simeone DM; Zalupski MM
Invest New Drugs; 2016 Dec; 34(6):733-739. PubMed ID: 27439894
[TBL] [Abstract][Full Text] [Related]
19. A two-cohort phase I study of weekly oxaliplatin and gemcitabine, then oxaliplatin, gemcitabine, and erlotinib during radiotherapy for unresectable pancreatic carcinoma.
Raftery L; Tepper JE; Goldberg RM; Blackstock AW; Aklilu M; Bernard SA; Ivanova A; Davies JM; O'Neil BH
Am J Clin Oncol; 2013 Jun; 36(3):250-3. PubMed ID: 22547007
[TBL] [Abstract][Full Text] [Related]
20. A phase 1 study of fixed dose rate gemcitabine and irinotecan in patients with advanced pancreatic and biliary cancer.
Sun W; Hewitt MR; Theobald MR; Hershock D; Haller DG
Cancer; 2007 Dec; 110(12):2768-74. PubMed ID: 17932893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]